Trial · NCT01393457

Cognitive Remediation for Cocaine Dependence

NCT01393457, Phase 2, Completed, The University of Texas Health Science Center, Houston; results first posted 2018-03-29

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Cognitive Remediation for Cocaine Dependence. Trials, record NCT01393457. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01393457

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Cognitive Remediation for Cocaine Dependence
NCT number: NCT01393457
Status: Completed
Phases: Phase 2
Enrollment: 119 participants, actual
Lead sponsor: The University of Texas Health Science Center, Houston
Conditions: Cocaine Dependence
Interventions: levodopa/carbidopa, Ropinirole 2 mg/d, Placebo, Ropinirole 4 mg/d
First posted: 2011-07-13
Last updated: 2018-03-29
Results first posted: 2018-03-29

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Cocaine Use Based on Urine Drug Screening	10 weeks	The mean of the predicted probabilities (derived from generalized linear mixed models) of negative drug screens over all 10 weeks is reported, as per the analysis proposed in the protocol.
Secondary	Number of Participants Who Completed the 10 Week Trial	10 weeks

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Cocaine Use Based on Urine Drug Screening	10 weeks	intention to treat	number of negative drug screens	MEAN
SECONDARY	Number of Participants Who Completed the 10 Week Trial	10 weeks		participants	NUMBER

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Cocaine Use Based on Urine Drug Screening	Ldopa + Ropinirole Low Dose	20.36	Standard Deviation 29.51	number of negative drug screens
Cocaine Use Based on Urine Drug Screening	Ldopa + Ropinirole High Dose	15.57	Standard Deviation 21.96	number of negative drug screens
Cocaine Use Based on Urine Drug Screening	Ldopa	22.3	Standard Deviation 28	number of negative drug screens
Cocaine Use Based on Urine Drug Screening	Placebo	27.8	Standard Deviation 30.35	number of negative drug screens
Number of Participants Who Completed the 10 Week Trial	Ldopa + Ropinirole Low Dose	14		participants
Number of Participants Who Completed the 10 Week Trial	Ldopa + Ropinirole High Dose	14		participants
Number of Participants Who Completed the 10 Week Trial	Ldopa	16		participants
Number of Participants Who Completed the 10 Week Trial	Placebo	15		participants

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Ldopa + Ropinirole Low Dose	26
Overall Study	STARTED	Ldopa + Ropinirole High Dose	26
Overall Study	STARTED	Ldopa	31
Overall Study	STARTED	Placebo	27
Overall Study	COMPLETED	Ldopa + Ropinirole Low Dose	14
Overall Study	COMPLETED	Ldopa + Ropinirole High Dose	14
Overall Study	COMPLETED	Ldopa	16
Overall Study	COMPLETED	Placebo	15
Overall Study	NOT COMPLETED	Ldopa + Ropinirole Low Dose	12
Overall Study	NOT COMPLETED	Ldopa + Ropinirole High Dose	12

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
serious	Chest pain	Cardiac disorders	Ldopa + Ropinirole Low Dose	0	26	0
serious	Chest pain	Cardiac disorders	Ldopa + Ropinirole High Dose	0	26	0
serious	Chest pain	Cardiac disorders	Ldopa	0	31	0
serious	Chest pain	Cardiac disorders	Placebo	1	27	1
serious	Weight gain	Metabolism and nutrition disorders	Ldopa + Ropinirole Low Dose	0	26	0
serious	Weight gain	Metabolism and nutrition disorders	Ldopa + Ropinirole High Dose	0	26	0
serious	Weight gain	Metabolism and nutrition disorders	Ldopa	0	31	0
serious	Weight gain	Metabolism and nutrition disorders	Placebo	1	27	1
serious	Gout flare up	Immune system disorders	Ldopa + Ropinirole Low Dose	0	26	0
serious	Gout flare up	Immune system disorders	Ldopa + Ropinirole High Dose	0	26	0

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Ldopa + Ropinirole Low Dose	0	26
Total, all-cause mortality	Ldopa + Ropinirole High Dose	0	26
Total, all-cause mortality	Ldopa	0	31
Total, all-cause mortality	Placebo	0	27
Total, other adverse events	Ldopa + Ropinirole Low Dose	0	26
Total, other adverse events	Ldopa + Ropinirole High Dose	0	26
Total, other adverse events	Ldopa	0	31
Total, other adverse events	Placebo	0	27
Total, serious adverse events	Ldopa + Ropinirole Low Dose	0	26
Total, serious adverse events	Ldopa + Ropinirole High Dose	1	26

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
34600245	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01393457

GET https://conductscience.org/api/trials/v1/NCT01393457/registered

API reference For AI assistants